Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    ISSN: 1434-0879
    Schlagwort(e): Key words Recombinant human erythropoietin ; Renal cortical blood flow ; Endothelin ; Selective endothelin-A receptor antagonist ; Hypertension
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract We have confirmed that renal cortical blood flow (RCBF) is significantly decreased by recombinant human erythropoietin (EPO). Endothelin-1 (ET1) is thought to be a mediator because its level increased significantly when EPO was administered. The present study was performed to clarify the effect of a selective ET-A receptor antagonist, S-0139, on EPO-induced RCBF reduction. Ten-week-old male Wistar rats, weighing about 250 g, were divided into five groups. Group 1 (n= 5), a control group, received normal saline solution (NSS). Group 2 (n= 5) received 200 U/kg body weight (BW) per hour of EPO. Group 3 (n= 5) received 400 U/kg BW per hour of EPO. Group 4 (n= 5) received both 200 U/kg BW per hour of EPO and 4 mg/kg BW per hour of S-0139. Group 5 (n= 5) received both 200 U/kg BW per hour of EPO and 40 mg/kg BW per hour of S-0139. Drugs were administered intravenously via the right femoral vein using a microinfusion pump for 4 h under urethane anesthesia. The RCBF was measured every 30 min by the hydrogen gas clearance method. When the 4 h had elapsed, the concentrations of plasma creatinine (Cr), ET1 and renin activity (RA) were measured. Compared with group 1, groups 2 and 3 showed significant (P 〈 0.001) decreases of RCBF, while the ET1 levels of these two groups increased significantly (P 〈 0.03). The ET1 of groups 4 and 5 also increased significantly (P 〈 0.03), however, the RCBF of these two groups did not decrease. No significant differences were observed in either Cr or RA between the five groups. EPO induces ET1 secretion. The reduction of RCBF is due to ET1-derived vasoconstriction. S-0139 has potential for preventing EPO-induced and ET1-mediated RCBF reduction.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Digitale Medien
    Digitale Medien
    Bognor Regis [u.a.] : Wiley-Blackwell
    Journal of Polymer Science Part A: Polymer Chemistry 35 (1997), S. 377-383 
    ISSN: 0887-624X
    Schlagwort(e): biodegradability ; poly(lactic acid) ; lactic acid-depsipeptide copolymer ; ring-opening copolymerization ; functionalized side-group ; Chemistry ; Polymer and Materials Science
    Quelle: Wiley InterScience Backfile Collection 1832-2000
    Thema: Chemie und Pharmazie
    Notizen: Since poly(lactic acid) is the biodegradable polyester having low immunogenicity and good biocompatibility, it is utilized as a medical material. However, poly(lactic acid) is a water-insoluble crystalline polymer having no reactive side-chain group. Thus, the use of poly(lactic acid) is limited. To modify the properties of poly(lactic acid) and to introduce the functionalized pendant groups to poly(lactic acid), we synthesized two kinds of lactic acid-depsipeptide copolymers with reactive pendant groups, namely poly[LA-(Glc-Lys)] and poly[LA-(Glc-Asp)]. This was done through ring-opening copolymerizations of L-lactide with the corresponding protected cyclodepsipeptides, cyclo[Glc-Lys(Z)] and cyclo[Glc-Asp(OBzl)], and subsequent deprotection of benzyloxycarbonyl and benzyl groups, respectively. By changing the mole fraction of the corresponding depsipeptide units, the solubility, thermal transition and degradation behavior of the modified poly(lactic acid) could be varied. © 1997 John Wiley & Sons, Inc.
    Zusätzliches Material: 2 Ill.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...